Cheap GLP-1s soon?

Hong Kong Yanpep International
Generic sema at $3 manufacturing is plausible - the molecule is not complex at scale. Patent expiry is what holds the price; once it goes, the competitive compression is usually fast.
 
The $50 Medicare/Medicaid deal has stipulations that narrow who actually qualifies - the gap for people who don't qualify hasn't changed. The patent cliff is the real price mechanism; the political announcements are claiming credit for what market competition was already set to deliver.
 
The Canadian patent timeline was earlier than the US one, which is why providers there were already talking about it last year. The transition from brand to generic usually takes several months after patent expiry for the first approved alternatives to reach pharmacy shelves.
 
Everyone reading this, name three categories of things you're currently paying less for compared to a year ago, and share your answers.

I can only come up with one for myself, and that's this drug class.
 
Over in India a GLP-1 is bought almost like any ordinary product, an open market. In America you get a monopoly, or a duopoly for the nitpickers. Over thirty generic versions of sema reached Indian pharmacies, pushing monthly out-of-pocket cost down to $14-$50. Imagine walking in with $50 and no insurance whatsoever, and leaving with a full month of the drug plus change back. So how well is the US system doing, exactly?
 
You must log in or register to reply here.
Back
Top